Genomma Lab Internacional Reports Fourth Quarter and Full Year 2021 Results

MEXICO CITY, February 23, 2022 /PRNewswire/ — Genomma Lab International, SAB de CV. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the fourth quarter and the year ended the 31st of December2021. All figures included in this document are expressed in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS).

The following tables present an abbreviated income statement, in millions of Mexican pesos. The margin for each figure represents its ratio to net sales and the percentage change in the fourth quarter and full year 2021 compared to the same audited period in 2020:


Q4 2021

% Sales

Q4 2020(2)

% Sales

Var. %

Net sales

4,062.7

100.0%

3,471.4

100%

+17.0%

Gross profit

2,562.0

63.1%

2,158.2

62.2%

+18.7%

Operating result

850.7

20.9%

680.9

19.6%

+24.9%

EBITDA(1)

889.9

22.0%

720.3

20.7%

+23.6%

Net revenue

359.2

8.8%

326.8

9.4%

+9.9%


FISCAL YEAR 2021

% Sales

FISCAL YEAR 2020(2)

% Sales

Var. %

Net sales

15,459.7

100.0%

13,870.2

100.0%

+11.5%

Gross profit

9,549.0

61.8%

8,588.1

61.9%

+11.2%

Operating result

3,062.9

19.8%

2,768.0

20.0%

+10.7%

EBITDA(1)

3,215.8

20.8%

2,923.0

21.1%

+9.8%

Net revenue

1,451.0

9.4%

1,470.4

10.6%

(1.3)%



1)

EBITDA defined as operating profit before depreciation.

2)

Fiscal 2020 audit adjustments were assigned to the fourth quarter of 2020, as disclosed in this document

Strong points

  • FY2021 sales increased by Ps. 1.59 billion; +11.5% over one year
  • FY-2021 EBITDA up +10.0% with a margin of 20.8%
  • FY2021 operating profit increased by Ps. 294.9 million; +10.7% over one year
  • Q4-2021 Net Debt to EBITDA ratio closed at 1.45x
  • Capex investments for the twelve months ended December 31, 2021 reached Ps. 616.6 million.

For a full version of Genomma Lab’s fourth quarter and full year 2021 earnings release, please visit: https://inversionistas.genommalab.com/en/financial-information

TELECONFERENCE INFORMATION:

Genomma Lab will hold a conference call on Thursday, February 24, 2022 to discuss these results. 11:00 a.m. Eastern Time / 10:00 a.m. central time (Mexico time).

To access the call, please dial:
+1 877-407-0784 (from USA)
+1 201-689-8560 (from outside the US)

If you prefer to receive a call rather than dial a number, please register via the following link. Please use this option 10-15 minutes prior to the conference call start time: Call Me Link

Entrants who do not wish to be interrupted to have their information collected can request the provider to call them by clicking the link above, filling in the information and pressing the green phone button at the bottom. The telephone number provided will be automatically called and connected to the conference without any interruption for the participant. (Please note: Participants will be joined directly to the conference and will hear music on hold until the call begins. No confirmation message will play when they are joined.)

Webcast:
There will also be a live audio webcast of the event at: Genomma Fourth Quarter and Full Year 2021 Earnings Call

Replay:
+1 844-512-2921 (USA)
+1 412-317-6671 (International)
Replay ID: 13726888
Available until March 3, 2022


On
Genomma Lab Internacional, SAB de CV is one of the leading pharmaceutical and personal care companies in Mexico with a growing international presence. Genomma Lab develops, sells and markets a wide range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab is built on the combination of a successful new product development process, consumer-focused marketing, an extensive retail distribution network, and a low-cost, high-performance operating model. flexible.

Genomma Lab shares are listed on the Mexican Stock Exchange under the symbol “LAB B” (Bloomberg: LABB: MM).

Note on forward-looking statements
This report may contain certain forward-looking statements and information relating to the Company that reflect the current beliefs and/or expectations of the Company and its management regarding its performance, business and future events. Forward-looking statements include, but are not limited to, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words such as “believe”, “anticipate”, “would expect”, “intend”, “will likely result”, or any other word or phrase of similar meaning. These statements are subject to a number of risks, uncertainties and assumptions. We caution you that a certain number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks relating to the impact of the global pandemic the of COVID19, such as the extent and duration of the outbreak, government actions and restrictive measures implemented in response, significant delays, supply chain disruptions and other impacts to the business, or the Company’s ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products obtained by competitors; challenges inherent in developing new products; the Company’s ability to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, either internally or within the supply chain; material adverse litigation or governmental action, including related to product liability claims; changes in applicable laws and regulations, including tax laws; changes in behavior and spending patterns of buyers of products and services; financial instability of international economies and legal systems and sovereign risk. A list and additional descriptions of such risks, uncertainties and other factors are contained in the Company’s filings with Bolsa Mexicana de Valores. Any forward-looking statements made in this release speak only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Genomma Lab International, SAB de CV

Comments are closed.